Skip to content

Study · Randomized controlled trial · 2014

1 result

Oral desmopressin lyophilisate (MELT) for monosymptomatic enuresis: structured versus abrupt withdrawal.

Ferrara P, Romano V, Cortina I, Ianniello F, Fabrizio GC, Chiaretti A

Journal of pediatric urology19 Jun 2013Cited by 23 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In children with monosymptomatic enuresis, relapse was similar after structured versus abrupt desmopressin withdrawal, 47.83% versus 45.83%.

    In plain wordsIn children with bedwetting, gradual desmopressin withdrawal did not reduce relapse compared with abrupt withdrawal.

    Outcome
    No significant changeRelapse one month after withdrawal
    Study

    n: not reported in source

    Comparator
    abrupt desmopressin withdrawal
    Analysis
    Primary
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    120 mcg/day, then 60 mcg/day for 15 days and 60 mcg every second evening for 15 days · sublingual · 3 months before withdrawalAs given in this study (human).

    Measurements

    Relapse
    47.83%
    structured withdrawal
    Relapse
    45.83%
    abrupt withdrawal
    P value
    0.89 unitless
    reported result

    Source sentences

    Summary
    Relapse rate at 1 month after the end of treatment was 47.83% in the group on a structured program versus 45.83% in the abrupt termination group (p = 0.89).
    3 context sentences
    Summary · context
    Eighty-one children, aged between 5½ and 14 years (mean age 8.64 years), were treated with MELT at a dosage of 120 mcg a day.
    Summary · context
    Responders were randomized to been withdrawn from therapy, after 3 months, abruptly or in a structured withdrawal program (60 mcg/day for 15 days and then 60 mcg every second evening for another 15 days).
    Summary · context
    Main outcome parameter was relapse rate 1 month after the end of treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.